

Global Effect of *rpoB* Mutation on Protein Expression in *Enterococcus faecium*

Xiaoting Hua,¹ Tingting Qu,² Xi Li,¹ Qiong Chen,¹ Zhi Ruan,¹ and Yunsong Yu^{1*}

¹Department of Infectious Diseases, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China

²State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China

*Corresponding author: Yunsong Yu, Department of Infectious Diseases, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China. Tel: +86-57186090073, Fax: +86-57186044817, E-mail: yyys119@163.com

Received 2016 February 23; Revised 2016 October 19; Accepted 2016 October 19.

Abstract

Background: *Enterococcus faecium* is an important nosocomial pathogen and has developed resistance to multiple antibiotics, such as vancomycin. Nitrofurantoin is active against *E. faecium* and *E. faecalis*, including vanA- and vanB-positive isolates.

Objectives: To investigate the role of *rpoB* mutation in *E. faecium*.

Methods: The growth rate and reactive oxygen species (ROS) levels were determined. The proteomic profiles of *E. faecium* B42 and its Rif^r mutant B42-R7 were also compared. Complement experiments were performed to elucidate the role of nitroreductase in nitrofurantoin resistance.

Results: The Rif^r mutant (B42-R7, *rpoB* H489D) of *E. faecium* had a lower growth rate and higher ROS levels. Overexpression of nitroreductase in *E. faecium* B42-R7 was observed in proteomic analyses. Enhanced expression of nitroreductase in *Escherichia coli* increased the sensitivity to nitrofurantoin.

Conclusions: The *rpoB* mutation in *E. faecium* not only altered the susceptibility to rifampin, but also affected global protein expression, including nitroreductase. Nitroreductase expression in *E. faecium* B42-R7 might play a role in nitrofurantoin resistance.

Keywords: *Enterococcus faecium*, *rpoB*, nitrofurantoin, nitroreductase

1. Background

Enterococcus faecium is an important nosocomial pathogen. Notably, expression of nitroreductase, it has developed resistance to multiple antibiotics, including vancomycin (1). The emergence of vancomycin resistance is most commonly found in *E. faecium*, and the incidence of *E. faecium* infections is increasing; thus, treatment of these infections is difficult (2). Nitrofurantoin belongs to a group of compounds characterized by the presence of one or more nitro-groups on a nitroaromatic or nitro-heterocyclic backbone. It is taken orally, rapidly absorbed and excreted in the urine to generate high therapeutic concentrations (3).

Nitrofurantoin is active against *E. faecium* and *E. faecalis*, and it retains its activity against vanA- and vanB-positive isolates (4). Although the specific mode of action of nitrofurantoin is still unknown, strains resistant and susceptible to nitrofurantoin differ in their ability to reduce various compounds (3). Stein et al. (5) reported that the mutants lacking nitroreductases are more resistant to nitrofurantoin due to their decreased activity.

Du et al. (6) obtained a *E. faecium* Rif^r mutant in a previous study. Rif^r mutants were isolated spontaneously from rifampin plates. We determined the growth rate and reac-

tive oxygen species (ROS) levels to further characterize this mutant (B42-R7, *rpoB* H489D). We also compared the proteomic profiles of *E. faecium* B42 and its Rif^r mutant B42-R7. The induced nitroreductase in B42-R7 may explain why B42-R7 became susceptible to nitrofurantoin.

2. Methods

2.1. Bacterial Strains, Media and Antibiotics

Restriction enzymes, T4 ligase, and Taq DNA polymerase were purchased from TaKaRa (Otsu, Shiga, Japan). All *Enterococci* cultures were grown at 37°C in Brain-Heart Infusion (BHI) broth and agar (Oxoid, Basingstoke, UK) (Appendix 1 in Supplementary File). All *Escherichia coli* cultures were grown at 37°C in Luria-Bertani (LB) broth and agar (Oxoid, Basingstoke, UK). Nitrofurantoin MICs were determined by Etest (bioMérieux, France) on Mueller-Hinton (MH) agar (Oxoid, Basingstoke, UK).

2.2. Double Time Measurement

Growth was measured using two methods. The first method was performed as described previously (7). Briefly, 500 µL overnight culture of each strain was transferred to 50 mL of BHI. The culture was grown at 37°C while shaking

at 250 rpm. The dilutions were spread onto BHI agar plates after 2 hours (t_1) and 4 hours (t_2). The plates were incubated at 37°C, and the number of colony forming units (CFU) was determined. The doubling time (g) was calculated from $g = \ln 2 / ((\log_{10} N_2 - \log_{10} N_1) 2.303 / \Delta t)$, where N_1 is CFU per mL at t_1 , and N_2 is CFU per mL at t_2 . The second method used the Bioscreen C reader (Oy Growth Curves Ab Ltd., Finland) to determine the growth rate of the strains in BHI broth at 37°C (8). Six independent cultures per strain were grown overnight, diluted 1:1000 and aliquoted into a Bioscreen C plate in triplicate. The growth rate was estimated by an R script from an OD_{600} interval between 0.02 and 0.08.

2.3. ROS Measurement

Overnight-cultured bacteria were diluted 1:100 into 1 mL fresh BHI culture. The bacteria were harvested and washed with PBS after the dilutions and were incubated in 37°C for 2 hours. Then, bacteria were incubated with dichlorofluorescein-diacetate (DCFH-DA, 1 μ M) for 30 minutes at 37°C and washed with PBS. The fluorescence of the solution was measured using a spectrofluorometer (excitation, 500 nm; emission, 530 nm) (9). DCFH-DA was purchased from Molecular Probes, Inc. (Eugene, OR).

2.4. Preparation of Whole Cellular Extracts

Overnight cultures of *E. faecium* B42 and B42-R7 were diluted 1:100 in BHI and grown to an OD_{600} of 1.0 at 37°C at 250 rpm. Then, the bacteria were centrifuged for 5 min at $6000 \times g$ and washed three times with PBS. These experiments were repeated three times (10).

Cell pellets were resuspended in 1 mL of lysis buffer (9.5 M urea, 65 mM DTT, 4% (w/v) CHAPS and 0.2% IPG buffer) containing a protease inhibitor cocktail. The cells were lysed for 30 minutes at room temperature. Then, the cells were sonicated for 5 minutes (cycles of 10 seconds of sonication with 15 seconds intervals) on ice. The cell lysates were centrifuged for 30 minutes at $12,000 \times g$. Then, the supernatants were collected, and the protein concentrations were determined using Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA, USA). The prepared samples were stored at -80°C (10).

2.5. Two-Dimensional Electrophoresis (2-DE)

For 2-DE, 100 μ g and 400 μ g of proteins were loaded onto analytical and preparative gels, respectively. The Ettan IPGphor Isoelectric Focusing System (Amersham Biosciences, Buckinghamshire, UK) and pH 3-10 immobilized pH gradient (IPG) strips (13 cm, nonlinear, Amersham Biosciences, Buckinghamshire, UK) were used for isoelectric focusing (IEF). The IPG strips were rehydrated for 12 hours in 250 μ L of rehydration buffer containing the protein

samples. IEF was performed in four steps: 30 V for 12 hours, 500 V for 1 hour, 1000 V for 1 hour, 8000 V for 8 hours, and 500 V for 5 hours. The strips were then subjected to the second-dimensional electrophoresis after transfer onto 12.5% SDS-polyacrylamide gels. Electrophoresis was performed using the Hofer SE 600 system (Amersham Biosciences, Buckinghamshire, UK) at 15 mA per gel for 30 minutes, followed by 30 mA per gel until the bromophenol blue reached the end of the gel.

Protein spots in the analytical gels were visualized by silver staining. The preparative gels were stained using a modified silver staining method compatible with subsequent mass spectrometric analysis (11). The stained gels were scanned using UMax Powerlook 2110XL (UMax), and image analysis was performed using ImageMaster 2D Platinum (GE Healthcare, Sweden). Each paired spot was manually verified to ensure a high level of reproducibility between normalized spot volumes of gels produced in triplicate data. The overlapping measures ratio was chosen to identify protein expression changes, and proteins with a 1.5-fold or greater overlap ratio threshold filtering were considered differentially expressed. Three replicates were performed for each sample.

2.6. 2D Digestion

Protein spots were cut from the preparative gels, destained for 20 minutes in 30 mM potassium ferricyanide/100 mM sodium thiosulfate (1:1 v/v) and washed with Milli-Q water until the gels were destained. Each spot was lyophilized and digested overnight in 12.5 ng/mL trypsin. The peptides were extracted three times with 60% ACN/0.1% TFA. The extracts were pooled and dried completely by a vacuum centrifuge (12).

2.7. MALDI-TOF/TOF MS Analysis

The dry peptide samples were reconstituted in 2 μ L 20% ACN, spotted on a 384-well Opti-TOF stainless steel plate, and covered with 5 mg/ml cyano-4-hydroxycinnamic acid (CHCA) in 50% ACN and 0.1% trifluoroacetic acid (TFA) before being dried. MS and MS/MS data for protein identification were obtained using a MALDI-TOF-TOF instrument (4800 proteomics analyzer; Applied Biosystems, Framingham, MA). Instrument parameters were set using the 4000 Series Explorer software (Applied Biosystems, Framingham, MA). The MS spectra were recorded in reflector mode in a mass range from 800 to 4000 Da with a focus mass of 2000 Da. MS was used with a CalMix5 standard to calibrate the instrument (ABI 4700 Calibration Mixture). For one major MS spectrum, 25 sub-spectra with 125 shots per sub-spectrum were accumulated using a random search pattern. For MS calibration, autolysis peaks of trypsin ([M

+H]⁺ 842.5100 and 2,211.1046) were used as internal calibrators. Additionally, up to 10 of the most intense ion signals were selected as precursors for MS/MS acquisition, excluding the trypsin autolysis peaks and the matrix ion signals. In MS/MS positive ion mode, for one major MS spectrum, 50 sub-spectra with 50 shots per sub-spectrum were accumulated using a random search pattern. Collision energy was 2 kV, collision gas was air, and default calibration was set by using the Glut-Fibrino-peptide B ([M + H]⁺ 1,570.6696) spotted onto Cal 7 positions of the MALDI target.

Combined peptide mass fingerprinting PMF and MS/MS queries were performed using the MASCOT search engine 2.2 (Matrix Science, Ltd.) embedded into GPS-Explorer Software 3.6 (Applied Biosystems) on the NCBI database (downloaded 2011-12-29) with the following parameter settings: 100 ppm mass accuracy, trypsin cleavage one missed cleavage allowed, carbamidomethylation set as fixed modification, oxidation of methionine was allowed as variable modification, MS/MS fragment tolerance was set to 0.4 Da. A GPS Explorer protein confidence index ≥ 95% was used for further manual validation.

2.8. Complementation Experiments

The *E. faecium* B42 nitroreductase gene was PCR-amplified from genomic wild-type DNA and ligated into the *E. coli-Enterococcus* shuttle vector pDL276 to generate the plasmid pDL276-NR. The pDL276-NR plasmid and pDL276 plasmid were transformed into *E. coli* DH5 α cells, and transformants were selected for their ability to grow on kanamycin. Transformation was confirmed by PCR amplification and sequencing of the *kana*^R gene in pDL276. Nitrofurantoin MICs of transformants were determined by Etest on Mueller-Hinton (MH) agar (Oxoid, Basingstoke, UK).

The nitroreductase gene was also sub-cloned into pBSU101 to generate the plasmid pBSU101-NR. Both pBSU101 and pBSU101-NR were transformed into *E. faecium* ATCC 35667. Nitrofurantoin MICs of DH5 α cells harboring pBSU101 or pBSU101-NR were determined by Etest on BHI agar.

3. Results

3.1. *rpoB* H489D Had a Lower Growth Rate and Higher ROS Levels

To determine whether the mutation in *rpoB* resulted in a fitness cost, we measured the doubling time for exponentially growing cells using two methods and assessed the wild type, B42-R7 and B42-R8. B42-R8 showed similar growth rates as the wild type (Figure 1). However, B42-R7 had a lower growth rate than the wild type. A similar trend

was also reported for *rpoB* mutants of *Deinococcus radiodurans* (7).





Figure 1. Double Time of *E. faecium* B42 (Wild-Type Strain), B42-R7 (*rpoB*-H489D) and B42-R8 (*rpoB*-H489P) in BHI Detected by BioscreenC Reader and Plating

We also measured the intracellular ROS levels of wild type and mutants. B42-R7 had higher intracellular ROS levels than those of the wild type (Figure 2). The *rpoB* H489P mutation did not induce intracellular ROS.

Figure 2. Intracellular ROS Levels in *E. faecium* B42 (Wild-Type Strain), B42-R7 (*rpoB*-H489D) and B42-R8 (*rpoB*-H489P)



The bacteria were incubated with 1 μ M DCFH-DA for 30 min at 37°C and washed with PBS. The fluorescence in the solution was measured using a spectrofluorometer (excitation, 500 nm; emission, 530 nm).

3.2. Two-Dimensional Gel Analysis of Differentially Expressed Proteins of *E. faecium* and Its Rif^r *RpoB* H489D Mutants

In order to investigate the proteomic response and possible proteins involved in nitrofurantoin resistance, we compared the proteomic profiles of *E. faecium* B42 and its Rif^r mutant B42-R7. We identified a total of 63 spots

with altered expression, including 24 spots that were up-regulated and 39 spots that were down-regulated (Appendix 2 in Supplementary File). After analysis using a 1.5 fold-change filter, 6 spots were up-regulated, and 15 spots were down-regulated. After the 6 and 15 spots were identified by MALDI-TOF/TOF MS/MS mass spectrometry, we obtained 4 and 11 proteins, respectively (Table 1 Appendix 3 in Supplementary File). These proteins included (1) proteins with a known nitrofurantoin resistance function; (2) metabolism-related proteins, which are necessary for growth, especially those related to glycolysis, energy production and conversion, and nucleotide transport and metabolism; (3) proteins related to translation and transcription; (4) a hypothetical protein: signal peptide.

In addition, we identified the same protein in two spots, which indicated different molecular weights, such as nitroreductase and GAPDH-I. Spot 1356 and spot 540 were identified as nitroreductase. Additionally, GAPDH-I was identified as spot 692 and spot 269. Spot 1356 and 692 were selected as nitroreductase and GAPDH-I by considering pI value, molecular weight and expression level. The identification of two spots as one protein may be due to the existence of homodimers of protein in 2D gels.

Nitroreductase (69246358) was up-regulated in B42-R7. Nitroreductase catalyzes the reduction of nitroaromatic compounds, such as nitrotoluenes and nitrofurans. Studies in *E. coli* showed that nitrofurans need to be activated by reducing activity for the antibiotic effect. The reduction of activity would thus indicate the nitrofurans sensitivity of the bacteria (3). The induced nitroreductase may explain why B42-R7 became susceptible to nitrofurantoin.

Most metabolism-related proteins that are necessary for growth, especially those related to glycolysis, energy production and conversion, and nucleotide transport and metabolism, were suppressed in the *rpoB* mutant. For nucleotide transport and metabolism, adenylosuccinate synthetase, which is involved in de novo biosynthesis of AMP, was identified. For synthesis of amino acids, 3-dehydroquinate synthase, which participates in the biosynthesis of amino acids, such as phenylalanine, tyrosine and tryptophan, was analyzed. Phospho-2-dehydro-3-deoxyheptonate aldolase is an intermediate of the synthesis of chorismate from shikimic acid (13). Shikimic acid is a precursor to the aromatic amino acids, phenyl alanine and tyrosine, and was previously obtained by McCalla and Neish (14). Glutathione reductase, also known as GSR or GR, is an enzyme that reduces glutathione disulfide (GSSG) to the sulfhydryl form GSH, an important cellular antioxidant (15). Three of the metabolism-related proteins were induced. GAPDH plays a prominent role in glycolysis in the cytosol. It also participates in tRNA transport, stimulates transcriptional activity, and controls DNA replication and

DNA repair (16-19). Additionally, 2-phospho-D-glycerate hydro-lyase participates in glycolysis/gluconeogenesis.

Tyrosyl-tRNA synthetase is involved in protein synthesis. Down-regulated tyrosyl-tRNA synthetase indicated that the bacteria's capacity to synthesize proteins was limited. The bacteria would logically increase their enzymes such as tRNA synthetase in order to enhance its capacity to synthesize proteins, thus evading the effect of the *rpoB* mutation. Two proteins without a COG class were identified. They should be investigated further as a potential functional proteins. One of the proteins, an up-regulated transcription activator, and the other protein, a down regulated signal peptide of the YSIRK family.

3.3. Overexpression of Nitroreductase Leads to Sensitivity to Nitrofurantoin

Given that nitroreductase was up-regulated in the *rpoB* H489D mutant as determined by a 2D-gel, we investigated whether the overexpression of nitroreductase would result in the same phenotype as the *rpoB* H489D mutant. Recombination expression vectors harboring the nitroreductase gene were introduced to *E. coli* and *E. faecium*. The Etest results showed that overexpression of nitroreductase enhanced the sensitivity of both *E. coli* and *E. faecium* to nitrofurantoin, indicating that nitroreductase played a role in nitrofurantoin susceptibility (Figure 3).

4. Discussion


One of the isolated Rif^r mutants (*rpoB*-H489D) of *E. faecium* presented lower growth rates and higher ROS levels. Therefore, in this study, we used 2-DE to investigate the global proteome altered by the *rpoB* mutation in *E. faecium*.

Breeze et al. (20) reported that the precise mode of action of the nitrofurantoin is still not clear. Nitrofurantoin exerts its antibiotic effects through two pathways. First, nitroreductase catalyzes the reduction of nitrofurantoin to form bactericidal end-products, which bind to DNA and proteins and inhibit nucleic acid synthesis. Studies in *E. coli* showed that nitrofurans required reduction for the antibiotic effect. Sandegren et al. (3) reported that the ability to reduce these compounds indicated the nitrofurans sensitivity of the bacteria. Second, nitrofurantoin had a direct effect on DNA. Breeze et al. (20) reported that DNA repair-defective mutants were also sensitive to nitrofurantoin.

Nitroreductase (69246358) was up-regulated in the *rpoB* mutant (B42-R7) in proteome analysis. The overexpression of nitroreductase in *E. coli* provided further evidence that the sensitivity to nitrofurantoin was caused by nitroreductase. Additional effects caused by *rpoB* mutation, except the rifampicin resistance, have been demonstrated in many bacteria. Ingham et al. (21) reported the

Table 1. Significantly and Differentially Expressed Proteins in *E. faecium* (> 1.5 fold) Identified by MALDI-TOF/TOF MS/MS

Spot no	NCBI GI identifier	COG	Protein description	Theor. Mass	Score	Sequence Coverage%	Theor. pI	Location	Gene	Fold change	SD
Protein Down-Regulated in B42-R7											
649	227552066	G	glyceraldehyde-3-phosphate dehydrogenase	35912.2	428	60	5.26	C	gap-2	-4.87057	0.967097
770	227551650	E	3-dehydroquinate synthase	38490.4	170	18	5.56	C	aroB	-2.70866	0.708657
1255	257867607	TK	transcriptional regulator	26393.8	176	25	5.12	C		-10.5638	1.053339
476	69247805	C	Glutathione reductase, animal and bacteria	49718.3	699	56	5.55	C		-2.06685	0.172891
269	69249876	G	Glyceraldehyde-3-phosphate dehydrogenase, type I	36362.4	517	51	4.92	C	GAPDH-I	-3.34061	1.799681
1476	314939418	-	signal peptide, YSIRK family	20884.4	178	31	8.69	CM		-2.25027	0.551905
880	257882793	MG	NAD-dependent epimerase/dehydratase	37782	83	19	5.4	C	WcaG	-2.38858	0.286398
569	227550654	F	adenylosuccinate synthase	47912.6	871	47	5.57	C	purA	-1.89042	0.132959
572	257900037	J	tyrosyl-tRNA synthetase	47550.4	288	22	5.28	C		-2.32279	0.454633
756	261207473	E	phospho-2-dehydro-3-deoxyheptonate aldolase	37513.2	397	40	5.83	C		-2.18216	0.784625
540	69246358	R	Nitroreductase	22292.2	526	72	5.05	C		-2.30057	1.044212
Protein Up-Regulated in B42-R7											
1356	69246358	R	Nitroreductase	22292.2	526	75	5.05	C		3.495866	0.03567
566	29839250	G	2-phospho-D-glycerate hydro-lyase	46382.4	476	26	4.58	C	eno	2.661148	0.595582
692	69249876	G	Glyceraldehyde-3-phosphate dehydrogenase, type I	36362.4	517	54	4.92	C	GAPDH-I	2.242169	0.808525
1609	257882505	-	transcription activator	17717.9	97	30	4.94	U		1.995636	0.202806

Figure 3. The Expression of Nitroreductase Increased the Sensitivity of Bacteria to Nitrofurantoin.

A, Nitrofurantoin MIC for DH5 α harbored pDL276 or pDL276-NR by E-Test; The *E. faecium* B42 nitroreductase gene was PCR amplified from genomic wild-type DNA and ligated into pDL276 to generate plasmid pDL276-NR; The plasmids pDL276-NR and pDL276 were transformed into *E. coli* DH5 α cells. Nitrofurantoin MICs of DH5 α harbored pDL276 or pDL276-NR were determined by Etest on BHI agar; B, Nitrofurantoin MIC for DH5 α harbored pBSU101 or pBSU101-NR by E-Test; The nitroreductase gene was sub-cloned into pBSU101 to generate plasmid pBSU101-NR. Both pBSU101 and pBSU101-NR were transformed into *E. faecium* ATCC 35667; Nitrofurantoin MICs of DH5 α harbored pBSU101 or pBSU101-NR were determined by Etest on BHI agar.

rpoB mutations (Q469K and Q469R) not only resulted in rifampicin resistance but also increased sensitivity to regulation by NusG in *Bacillus subtilis*. Maughan et al. (22) reported that mutations in *rpoB* of *B. subtilis* also led to a global change in the expression of a number of global phenotypes known to be under transcriptional control, such as growth, competence for transformation, sporulation, and germination. Gao et al. (23) reported that *rpoB* H481Y and an active stringent response caused global transcriptional changes and reduced virulence in *Staphylococcus aureus*. Kristich et al. (24) reported that a H486Y *rpoB* mu-

tant in enterococci resulted in alteration of intrinsic resistance towards 2nd and 3rd generation cephalosporins. The RNAP mutation affected the transcription of as-yet-unknown gene that was critical for cellular adaptation to cephalosporin stress. The mutant RNAP in *E. faecium* might mimic the stringent response to regulate the expression of nitroreductase.

The *rpoB* H489D mutant presented lower growth rates and higher ROS levels. Wells et al. (25) reported that the *rpoB* mutation restored prototrophy to ppGpp mutants by causing RNAP to mimic its behavior under stringent condi-

tions in *Sinorhizobium meliloti*. The *rpoB* mutation mimics the effects of the stringent response by altering transcription at the level of initiation, elongation, or the ability of core RNAP to bind various sigma factors. The lower growth rate provided further evidence that RNAP in the mutant functions as if it were under stringent conditions.

Most of the metabolism-related proteins that are necessary for growth, especially those related to glycolysis, energy production and conversion, and nucleotide transport. Most metabolism-related proteins that are necessary in the *rpoB* mutant. These results were consistent with the lower growth rate. We also found that glutathione reductase (an important cellular antioxidant) was down-regulated (15). The down-regulation of glutathione reductase indicated that the cell may have higher intracellular ROS levels. We verified this hypothesis via ROS measurement in the cells. Hua et al. (7) reported the same result in an *rpoB* mutant in *D. radiodurans*. The *rpoB* mutant in *D. radiodurans* also showed a lower growth rate and higher ROS levels.

Overall, an *rpoB* mutant of *E. faecium* showed a lower growth rate and higher ROS levels. The proteomic profile comparison of *E. faecium* B42 and its Rif^r mutant B42-R7 indicated that the *rpoB* mutation altered the transcription of nitroreductase and other genes related to growth. The *rpoB* mutation in *E. faecium* not only altered the susceptibility to rifampin but also affected global protein expression, including nitroreductase. Thus, nitroreductase in *E. faecium* B42-R7 might play a role in nitrofurantoin resistance.

Supplementary Material

Supplementary material(s) is available [here](#).

Acknowledgments

We thank Prof. Gary M. Dunny at the university of Minnesota for kindly providing the pDL276 plasmid used for the overexpression experiment and Prof. Barbara Spellerberg in Universitätsklinikum Ulm for the plasmid pBSU101. We thank Shanghai Applied Protein Technology Co., Ltd. for the technical support.

Footnotes

Authors' Contribution: Developed and designed the experiments: Xiaoting Hua and Tingting Qu; performed the experiments: Xiaoting Hua, Qiong Chen and Xi Li; analyzed the data: Xiaoting Hua and Zhi Ruan; contributed in reagents/materials/analysis tools: Xiaoting Hua; wrote the manuscript: Xiaoting Hua and Yunsong Yu.

Funding/Support: This work was supported by a research grant from the National Natural Science Foundation of China (no. NSFC81101284) and the Ministry of Health of the People's Republic of China (no. 201002021).

Role of the Sponsor: The funding organizations are public institutions and had no role in the design and management of the study; nor in collection, coordination and analysis of the data and preparation, review, and approval of the manuscript.

References

- Lam MM, Seemann T, Bulach DM, Gladman SL, Chen H, Haring V, et al. Comparative analysis of the first complete *Enterococcus faecium* genome. *J Bacteriol.* 2012;**194**(9):2334–41. doi: [10.1128/JB.00259-12](#). [PubMed: [22366422](#)].
- Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. *Emerg Infect Dis.* 1998;**4**(2):239–49. doi: [10.3201/eid0402.980211](#). [PubMed: [9621194](#)].
- Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. Nitrofurantoin resistance mechanism and fitness cost in *Escherichia coli*. *J Antimicrob Chemother.* 2008;**62**(3):495–503. doi: [10.1093/jac/dkn222](#). [PubMed: [18544599](#)].
- Zhanell GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin-resistant enterococci. *Antimicrob Agents Chemother.* 2001;**45**(1):324–6. doi: [10.1128/AAC.45.1.324-326.2001](#). [PubMed: [11120989](#)].
- Stein DC, Carrizosa E, Dunham S. Use of *nfsB*, encoding nitroreductase, as a reporter gene to determine the mutational spectrum of spontaneous mutations in *Neisseria gonorrhoeae*. *BMC Microbiol.* 2009;**9**:239. doi: [10.1186/1471-2180-9-239](#). [PubMed: [19930647](#)].
- Du X, Hua X, Qu T, Jiang Y, Zhou Z, Yu Y. Molecular characterization of Rif^r mutations in *Enterococcus faecalis* and *Enterococcus faecium*. *J Chemother.* 2014;**26**(4):217–21. doi: [10.1179/1973947813Y.0000000137](#). [PubMed: [24070269](#)].
- Hua X, Wang H, Wang C, Tian B, Hua Y. Global effect of an RNA polymerase beta-subunit mutation on gene expression in the radiation-resistant bacterium *Deinococcus radiodurans*. *Sci China Life Sci.* 2011;**54**(9):854–62. doi: [10.1007/s11427-011-4209-3](#). [PubMed: [21809039](#)].
- Linkevicius M, Sandegren L, Andersson DI. Mechanisms and fitness costs of tigecycline resistance in *Escherichia coli*. *J Antimicrob Chemother.* 2013;**68**(12):2809–19. doi: [10.1093/jac/dkt263](#). [PubMed: [23843301](#)].
- Tian B, Sun Z, Xu Z, Shen S, Wang H, Hua Y. Carotenoid 3',4'-desaturase is involved in carotenoid biosynthesis in the radioresistant bacterium *Deinococcus radiodurans*. *Microbiology.* 2008;**154**(Pt 12):3697–706. doi: [10.1099/mic.0.2008/021071-0](#). [PubMed: [19047737](#)].
- Wang X, He X, Jiang Z, Wang J, Chen X, Liu D, et al. Proteomic analysis of the *Enterococcus faecalis* V583 strain and clinical isolate V309 under vancomycin treatment. *J Proteome Res.* 2010;**9**(4):1772–85. doi: [10.1021/pr901216e](#). [PubMed: [20128627](#)].
- Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, et al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. *Electrophoresis.* 2000;**21**(17):3666–72. doi: [10.1002/1522-2683\(200011\)21:17<3666::AID-ELPS3666>3.0.CO;2-6](#). [PubMed: [11271485](#)].
- Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. *Anal Chem.* 2003;**75**(3):663–70. [PubMed: [12585499](#)].

13. D'Auria G, Jimenez-Hernandez N, Peris-Bondia F, Moya A, Latorre A. Legionella pneumophila pangenome reveals strain-specific virulence factors. *BMC Genomics*. 2010;**11**:181. doi: [10.1186/1471-2164-11-181](https://doi.org/10.1186/1471-2164-11-181). [PubMed: [20236513](https://pubmed.ncbi.nlm.nih.gov/20236513/)].
14. Mc CD, Neish AC. Metabolism of phenylpropanoid compounds in Salvia. I. Biosynthesis of phenylalanine and tyrosine. *Can J Biochem Physiol*. 1959;**37**(4):531-6. [PubMed: [13638873](https://pubmed.ncbi.nlm.nih.gov/13638873/)].
15. Meister A. Glutathione metabolism and its selective modification. *J Biol Chem*. 1988;**263**(33):17205-8. [PubMed: [3053703](https://pubmed.ncbi.nlm.nih.gov/3053703/)].
16. Tanaka R, Mochizuki H, Suzuki A, Katsube N, Ishitani R, Mizuno Y, et al. Induction of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. *J Cereb Blood Flow Metab*. 2002;**22**(3):280-8. doi: [10.1097/00004647-200203000-00005](https://doi.org/10.1097/00004647-200203000-00005). [PubMed: [11891433](https://pubmed.ncbi.nlm.nih.gov/11891433/)].
17. Morgeneegg G, Winkler GC, Hubscher U, Heizmann CW, Mous J, Kuenzle CC. Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and a possible activator of transcription in neurons. *J Neurochem*. 1986;**47**(1):54-62. [PubMed: [2423647](https://pubmed.ncbi.nlm.nih.gov/2423647/)].
18. Singh R, Green MR. Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. *Science*. 1993;**259**(5093):365-8. [PubMed: [8420004](https://pubmed.ncbi.nlm.nih.gov/8420004/)].
19. Baxi MD, Vishwanatha JK. Uracil DNA-glycosylase/glyceraldehyde-3-phosphate dehydrogenase is an Ap4A binding protein. *Biochemistry*. 1995;**34**(30):9700-7. [PubMed: [7626640](https://pubmed.ncbi.nlm.nih.gov/7626640/)].
20. Breeze AS, Obaseiki-Ebor EE. Mutations to nitrofurantoin and nitrofurazone resistance in Escherichia coli K12. *J Gen Microbiol*. 1983;**129**(1):99-103. doi: [10.1099/00221287-129-1-99](https://doi.org/10.1099/00221287-129-1-99). [PubMed: [6339681](https://pubmed.ncbi.nlm.nih.gov/6339681/)].
21. Ingham CJ, Furneaux PA. Mutations in the ss subunit of the Bacillus subtilis RNA polymerase that confer both rifampicin resistance and hypersensitivity to NusG. *Microbiology*. 2000;**146 Pt 12**:3041-9. doi: [10.1099/00221287-146-12-3041](https://doi.org/10.1099/00221287-146-12-3041). [PubMed: [11101662](https://pubmed.ncbi.nlm.nih.gov/11101662/)].
22. Maughan H, Galeano B, Nicholson WL. Novel rpoB mutations conferring rifampin resistance on Bacillus subtilis: global effects on growth, competence, sporulation, and germination. *J Bacteriol*. 2004;**186**(8):2481-6. [PubMed: [15060052](https://pubmed.ncbi.nlm.nih.gov/15060052/)].
23. Gao W, Cameron DR, Davies JK, Kostoulias X, Stepnell J, Tuck KL, et al. The RpoB H(4)(8)(1)Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus. *J Infect Dis*. 2013;**207**(6):929-39. doi: [10.1093/infdis/jis772](https://doi.org/10.1093/infdis/jis772). [PubMed: [23255563](https://pubmed.ncbi.nlm.nih.gov/23255563/)].
24. Kristich CJ, Little JL. Mutations in the beta subunit of RNA polymerase alter intrinsic cephalosporin resistance in Enterococci. *Antimicrob Agents Chemother*. 2012;**56**(4):2022-7. doi: [10.1128/AAC.06077-11](https://doi.org/10.1128/AAC.06077-11). [PubMed: [22290974](https://pubmed.ncbi.nlm.nih.gov/22290974/)].
25. Wells DH, Long SR. Mutations in rpoBC suppress the defects of a Sinorhizobium meliloti relA mutant. *J Bacteriol*. 2003;**185**(18):5602-10. [PubMed: [12949113](https://pubmed.ncbi.nlm.nih.gov/12949113/)].